Evidence map›Paper›PMID 29946874›Full record

ReviewDer Internist2018

[Bridging anticoagulation in patients receiving vitamin K antagonists : Current status].

S M Schellong, H Riess, M Spannagl, H Omran, M Schwarzbach, F Langer, W Gogarten, P Bramlage, R M Bauersachs

Abstract readReview
PubMed Publisher
In one paragraph

Review in Der Internist, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. [Perioperative management of platelet function and anticoagulation in geriatric patients].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2022
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 1 country.

S M SchellongMedizinische Klinik 2, Krankenhaus Dresden-Friedrichstadt, Friedrichstr. 41, 01067, Dresden, Deutschland. schellong-se@khdf.de.
H RiessMedizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie, Charité - Universitätsmedizin Berlin, Berlin, Deutschland.
M SpannaglHämostaseologie, Campus Innenstadt, Klinikum der Universität München, München, Deutschland.
H OmranSt. Marien Hospital, Bonn, Deutschland.
M SchwarzbachKlinik für Allgemein‑, Viszeral‑, Gefäß- und Thoraxchirurgie, Klinikum Frankfurt Höchst, Frankfurt, Deutschland.
F LangerII. Medizinische Klinik und Poliklinik, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland.
W GogartenKlinik für Anästhesiologie, operative Intensivmedizin, Notfallmedizin und Schmerztherapie, Klinikum Bielefeld, Bielefeld, Deutschland.
P BramlageInstitut für Pharmakologie und Präventive Medizin, Cloppenburg, Deutschland.
R M BauersachsKlinik für Gefäßmedizin - Angiologie, Klinikum Darmstadt GmbH, Darmstadt, Deutschland.
Charité - Universitätsmedizin Berlin · DEIPPMed (Germany) · DEKlinikum Bielefeld · DEKlinikum Frankfurt Höchst · DEKrankenhaus Dresden-Friedrichstadt · DESt. Marien-Hospital Bonn · DEUniversity Medical Center Hamburg-Eppendorf · DEUniversity Medical Center of the Johannes Gutenberg University Mainz · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Approximately 30% of patients receiving oral anticoagulation using vitamin K antagonists (VKA) require surgery within 2 years. In this context, a clinical decision on the need and the mode of a peri-interventional bridging with heparin is needed. While a few years ago, bridging was almost considered a standard of care, recent study results triggered a discussion on which patients will need bridging at all. Revisiting the currently available recommendations and study results the conclusion can be drawn that the indications for bridging with heparin must nowadays be taken more narrowly and considering the individual patient risk of bleeding and thromboembolism. Bridging with heparin is only needed in patients with a very high risk of thromboembolism. This overview aims to give guidance for a risk-adapted peri-interventional approach to management of patients with a need for long-term anticoagulation using VKA.

Indexed as

AnticoagulantsThromboembolismVitamin KAdministration, OralHumansPerioperative CareAnticoagulantsVitamin KHeparin, low molecular weightInternational Normalized RatioPerioperative careRisk, hemorrhageRisk, thromboembolism

Identifiers

PMID29946874
OpenAlexW2809599379

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.